[1] Younossi ZM, Koenig AB, Abdelatif D, et al.Global epidemiology of nonalcoholic fatty Liver disease-meta-analytic assessent of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. [2] 中华医学会内分泌学分会. 非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版)[J]. 中华内分泌代谢杂志,2018,34(7):2103-2108. [3] Davies BSJ.Can targeting ANGPTL proteins improve glucose tolerance?[J]. Diabetologia, 2018, 61(6): 1277-1281. [4] Zhang R, Abou-Samra AB.A dual role of lipasin (betatrophin) in lipid metabolism and glucose homeostasis: consensus and controversy[J]. Cardiovasc Diabetol, 2014, 13(1): 133. [5] Eslam M, Newsome PN, Sarin SK, et al.A new definition for metabolic dysfunction -associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020, 73: 202-209. [6] Haas JT, Francque S, Staels B.Pathophysiology and mechanisms of nonalcoholic fatty liver disease[J]. Annu Rev Physiol, 2016, 78: 181-205. [7] Williamson RM, Price JF, Glancy S, et al.Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study[J]. Diabetes Care, 2011, 34: 1139-1144. [8] Targher G, Bertolini L, Padovani R, et al.Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients[J]. Diabetes Care, 2007, 30: 1212-1218. [9] Michel PJ, Boris G, Beatrice T, et al.Nonalcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients[J]. J Clin Endocrinol Metab, 2009(10): 4103-4106. [10] 张林杉,卞华,颜红梅,等. 2型糖尿病患者肝脏脂肪含量与肝病结局的相关性研究[J]. 中华内分泌代谢杂志,2014,30(1):3-7. [11] Fernando B, Kenneth C.Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus[J]. Endocrinol Metab Clin North Am, 2016, 45: 765-781. [12] Wieneke D, Anne PB, Mikael L, et al.Angiopoietin-like 4 promotes intracellular degradation of lipoprotein lipase in adipocytes[J]. J Lipid Res, 2016, 57(9): 1670-1683. [13] Massimiliano R, Chiara M, Federica F, et al.Angiopoietin-like 3 and subclinical peripheral arterial disease: evidence from the Brisighella heart study[J]. Eur J Prev Cardiol, 2020, 27(19): 2251-2254. [14] Zhang R.The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking[J]. Open Biol, 2016, 6(4): 150272. [15] Yue S, Wu J, Zhang J, et al.The Relationship between Betatrophin Levels in Blood and T2DM: A Systematic Review and Meta-Analysis[J]. Disease markers, 2016, 2016(3): 1-7. [16] Chen X, Lu P, He W, et al.Circulating Betatrophin Levels Are Increased in Patients With Type 2 Diabetes and Associated With Insulin Resistance[J]. The Journal of Clinical Endocrinology and Metabolism, 2015(100): 96-100. [17] Gao T, Jin K, Chen P, et al.Circulating Betatrophin Correlates with Triglycerides and Postprandial Glucose among Different Glucose Tolerance Statuses--A Case-Control Study[J]. Plos One, 2015, 10(8): e0133640. [18] 隋淼. Betatrophin研究进展[J]. 医学研究生学报,2018,31(3):318-322. [19] Lee YH, Lee SG, Lee CJ, et al.Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies[J]. Scientific Reports, 2016, 6: 24013. [20] Wen H, Shao X, Guo D, et al.Relationship of Serum Betatrophin with Nonalcoholic Fatty Liver in a Chinese Population[J]. Plos One, 2017, 12(1): e0170758. [21] Ke Y, Liu S, Zhang Z, et al.Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis[J]. Lipids in health and disease, 2021, 20(1): 55. [22] Alper S, Teoman D, Cemal NE, et al.Betatrophin Levels Are Related to the Early Histological Findings in Nonalcoholic Fatty Liver Disease[J]. Metabolites, 2021, 11(7): 425. |